Literature DB >> 20101671

Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia.

Ranjit Akolekar1, Jader de Cruz, Jean-Michel Foidart, Carine Munaut, Kypros H Nicolaides.   

Abstract

OBJECTIVE: To investigate the maternal plasma concentration of soluble fms-like tyrosine kinase-1 (sFlt-1) and free vascular endothelial growth factor (free-VEGF) at 11 to 13 weeks of gestation in patients destined to develop preeclampsia (PE) and to examine whether any possible differences in maternal plasma levels are related to uterine artery pulsatility index (PI) and maternal serum placental growth factor (PlGF).
METHODS: Plasma free-VEGF, plasma sFlt-1, serum PlGF and uterine artery PI were measured at 11 to 13 weeks in 90 cases that subsequently developed PE and in 180 unaffected controls.
RESULTS: In the majority of cases of PE and controls the levels of free-VEGF were undetectable. In the pregnancies that developed PE, compared to unaffected controls, uterine artery PI was higher, serum PlGF was lower but there was no significant difference in levels of sFlt-1.
CONCLUSION: Measurement of free-VEGF and sFlt-1 in maternal blood at 11 to 13 weeks of gestation is not useful in the prediction of pregnancies destined to develop PE. Copyright (c) 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101671     DOI: 10.1002/pd.2433

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  8 in total

1.  miR-210 inhibits trophoblast invasion and is a serum biomarker for preeclampsia.

Authors:  Lauren Anton; Anthony O Olarerin-George; Nadav Schwartz; Sindhu Srinivas; Jamie Bastek; John B Hogenesch; Michal A Elovitz
Journal:  Am J Pathol       Date:  2013-09-10       Impact factor: 4.307

2.  Concentrations of endothelial nitric oxide synthase, angiotensin-converting enzyme, vascular endothelial growth factor and placental growth factor in maternal blood and maternal metabolic status in pregnancy complicated by hypertensive disorders.

Authors:  A Zawiejska; E Wender-Ozegowska; R Iciek; J Brazert
Journal:  J Hum Hypertens       Date:  2014-09-04       Impact factor: 3.012

Review 3.  First trimester prediction of preeclampsia.

Authors:  Ulrik Dolberg Anderson; Magnus Gram; Bo Åkerström; Stefan R Hansson
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

Review 4.  Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review.

Authors:  Marni Jacobs; Natasha Nassar; Christine L Roberts; Ruth Hadfield; Jonathan M Morris; Anthony W Ashton
Journal:  Reprod Biol Endocrinol       Date:  2011-06-08       Impact factor: 5.211

5.  First trimester serum placental growth factor and hyperglycosylated human chorionic gonadotropin are associated with pre-eclampsia: a case control study.

Authors:  Elina Keikkala; Sini Koskinen; Piia Vuorela; Hannele Laivuori; Jarkko Romppanen; Seppo Heinonen; Ulf-Håkan Stenman
Journal:  BMC Pregnancy Childbirth       Date:  2016-11-25       Impact factor: 3.007

6.  Maternal characteristics, mean arterial pressure and serum markers in early prediction of preeclampsia.

Authors:  Sylwia Kuc; Maria P H Koster; Arie Franx; Peter C J I Schielen; Gerard H A Visser
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

Review 7.  First trimester biomarkers in the prediction of later pregnancy complications.

Authors:  Stefan C Kane; Fabricio da Silva Costa; Shaun Brennecke
Journal:  Biomed Res Int       Date:  2014-03-30       Impact factor: 3.411

8.  Enhanced HIF2α expression during human trophoblast differentiation into syncytiotrophoblast suppresses transcription of placental growth factor.

Authors:  Tatsuya Fujii; Takeshi Nagamatsu; Kazuki Morita; Danny J Schust; Takayuki Iriyama; Atsushi Komatsu; Yutaka Osuga; Tomoyuki Fujii
Journal:  Sci Rep       Date:  2017-09-29       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.